

# Anti-Migraine Drugs: Market Research Report

<https://marketpublishers.com/r/A431247D60EEN.html>

Date: February 2010

Pages: 580

Price: US\$ 3,950.00 (Single User License)

ID: A431247D60EEN

## Abstracts

This report analyzes the US And European markets for Anti-Migraine Drugs in US\$ Million.

Annual forecasts are provided for the period 2006 through 2015.

A six-year historic Analysis is also provided for these markets.

The report profiles 53 companies including many key and niche players such as Abbott Laboratories, Inc., Eisai, Inc., Eisai, Inc, Johnson & Johnson, Inc., Kowa Pharmaceuticals America, Inc., MAP Pharmaceuticals, Inc., Merck & Co., Inc., Merck & Co., Inc., Poze, Poze., Winston Pharmaceuticals, Inc., Wyeth Consumer Healthcare, Zogenix, Inc., AstraZeneca Plc, Bayer AG, Ethypharm S.A., GlaxoSmithKline Plc, Meda AB, Novartis AG, and Novartis AG.

Market data and analytics are derived from primary and secondary research.

Company profiles are mostly extracted from URL research and reported select online sources.

## Contents

### I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability And Reporting Limitations  
Disclaimers  
Data Interpretation & Reporting Level  
Quantitative Techniques & Analytics  
Product Definitions and Scope of Study

### II-A. A US AND EUROPEAN MARKET REPORT

#### 1.MIGRAINE: AN OVERVIEW

What is Migraine?  
What Causes Migraine?  
Migraine Classification  
Migraine with Aura  
Migraine without Aura  
Aura without Headache  
Abdominal Migraine  
Facial Migraine  
Basilar Migraine  
Familial Hemiplegic Migraine  
Ophthalmoplegic/Ocular Migraine  
Retinal Migraine  
Menstrual Migraine  
Status Migraine  
Migraine Attack Stages  
I – The Prodrome Stage  
II – The Aura Stage  
III – The Headache Stage  
IV – The Postdrome Stage

#### 2.ANTI-MIGRAINE TREATMENT

Historical Perspective  
Migraine Treatment  
Abortive Drugs

Selective Serotonin Receptor (5- HTI) Agonists/ Triptans

Triptans Approved for the Treatment of Migraine

Ergot Alkaloids

Ergot Alkaloids for the Treatment of Migraine

Antiemetics

Antiemetics for the Treatment of Migraine

Analgesics

Analgesics for the Treatment of Migraine

Prophylactic Drugs

Beta-Blockers

Calcium Channel Blockers

Anticonvulsants

Tricyclic Antidepressants

Non-steroidal Anti-inflammatory Drugs

Selective Serotonin Reuptake Inhibitors

Serotonin Antagonists

Anti-migraine Drugs: Side Effects

Abortive Drugs: Side Effects

Prophylactic Drugs: Side Effects

Anti-migraine Drugs: Interactions

Abortive Medications: Interactions

Prophylactic Drugs: Interactions

### **3.RESEARCH & DEVELOPMENT**

Pipeline Drug Research

Pipeline Drug Candidates in Phase III Clinical Trials

Pipeline Drug Candidates in Phase II Clinical Trials

Clinical Research / Drug Development Initiatives

MAP Pharma Announces Positive Phase III Results for Levadex

Addex Initiates Phase IIb Trials for ADX 10059

Asterand and BTG Announce Plans to Commence Phase IIa Trials

Alexza Commences Phase IIb Trials of AZ-104

Neuralieve Announces Trial Completion of New Migraine Treatment Device

NeurAxon Announces Encouraging Results of Phase 2 Trials

Roxro Pharma Announces ROX-828 Results

Merck Announces Encouraging Results of Phase III Study of Telcagepant

ProEthic Pharmaceuticals Reports Encouraging Phase III Results

Recent Migraine Research

Study Reveals Cocoa Consumption to Ease Migraine  
Study Reveals Women with Migraine to be At Lesser Risk of Breast Cancer  
Study Shows Risk of Migraine to be Less Among High Blood Pressure Patients

## **II-B. REGIONAL MARKET PERSPECTIVE**

### **1.THE UNITED STATES**

#### **A. MARKET ANALYSIS**

Current & Future Analysis

Historic Analysis

Migraine – Prevalence and Economic Burden

Anti-Migraine Drugs Market At A Glance

Triptans – Leading the Anti-Migraine Treatment Race

Generic Imitrex Make Foray

Botox – An Emerging Option for Migraine Prophylaxis

Anti-migraine Drugs – Limitations Abound

The Quest to Unravel the Mystery of Cause of Migraine Continues...

Strategic Corporate Developments

Zogenix, Astellas Pharma Sign Agreement for Sumavel DosePro

Kowa Pharma to Divest Diclofenac Franchise

Zogenix Wins FDA Approval for Sumavel DosePro

Orchid Pharma Obtains FDA Approval for Sumatriptan Succinate Tablets

Sandoz Unveils Sumatriptan and Calcitonin- Salmon Nasal Spray

Wockhardt to Introduce Divalproex ER

Ranbaxy Receives FDA Approval for Imitrex Generic

Kowa America Secures FDA Approval for Cambia

Almirall Receives FDA Approval for Axert/ Almogran

Wockhardt Receives FDA Approval for Sumatriptan Injections

Teva Pharmaceutical Secures Approval, Launches Imitrex Generic

AstraZeneca Unveils Zomig Rapimeltt in 5 mg Dosage Strength

Bedford Laboratories Launches Sumatriptan Succinate Injection

Ipca Laboratories and Heritage Pharmaceuticals Announce Strategic Alliance

Dr. Reddy's Introduces Approved Imitrex® Generic

US FDA Approves Divalproex Sodium Tablets

GSK and Pozen Announce FDA Approval for Treximet

Aurobindo Wins Provisionary Approval for Sumatriptan Succinate Tablets

Par Pharmaceuticals to Commence Shipment of Imitrex's Generic Version

## Select Players

Abbott Laboratories, Inc.

Eisai, Inc.

Eli Lilly and Company

Johnson & Johnson, Inc.

Kowa Pharmaceuticals America, Inc.

MAP Pharmaceuticals, Inc.

Merck & Co., Inc.

Pfizer, Inc.

Pozen

Roxro Pharma, Inc.

Winston Pharmaceuticals, Inc.

Wyeth Consumer Healthcare

Zogenix, Inc.

## **B. MARKET ANALYTICS**

**Table 1.** US Recent Past, Current & Future Analysis for Anti-Migraine Drugs – Annual Sales Figures in US\$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart)

**Table 2.** US Historic Analysis for Anti-Migraine Drugs – Annual Sales Figures in US\$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart)

## **2.EUROPE**

### **A. MARKET ANALYSIS**

Current & Future Analysis

Historic Analysis

Strategic Corporate Developments

Orexo Acquires PharmaKodex

Noxxon Pharma Collaborates with Eli Lilly

Select Players

AstraZeneca Plc (UK)

Bayer AG (Germany)

Ethypharm S.A. (France)

GlaxoSmithKline Plc (UK)

Meda AB (Sweden)  
Novartis AG (Switzerland)  
UCB S.A. (Belgium)

## **B. MARKET ANALYTICS**

**Table 3.** European Recent Past, Current & Future Analysis for Anti-Migraine Drugs by Region – France, Germany, Italy, UK, Spain and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart)

**Table 4.** European Historic Analysis for Anti-Migraine Drugs by Region – France, Germany, Italy, UK, Spain and Rest of Europe Markets Independently Analyzed with Annual Sales Figure in US\$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart)

**Table 5.** European 15-year Perspective for Anti-Migraine Drugs by Region – Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain and Rest of Europe Markets for Years 2003, 2009 & 2015 (includes corresponding Graph/Chart)

## **2A.FRANCE**

### **A. MARKET ANALYSIS**

Current & Future Analysis  
Historic Analysis

### **B. MARKET ANALYTICS**

**Table 6.** French Recent Past, Current & Future Analysis for Anti-Migraine Drugs –Annual Sales Figures in US\$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart)

**Table 7.** French Historic Analysis for Anti-Migraine Drugs – Annual Sales Figures in US\$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart)

## **2B.GERMANY**

## **A. MARKET ANALYSIS**

Current & Future Analysis  
Historic Analysis

## **B. MARKET ANALYTICS**

**Table 8.** German Recent Past, Current & Future Analysis for Anti-Migraine Drugs – Annual Sales Figures in US\$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart)

**Table 9.** German Historic Analysis for Anti-Migraine Drugs – Annual Sales Figures in US\$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart)

## **2C.ITALY**

### **A. MARKET ANALYSIS**

Current & Future Analysis  
Historic Analysis

### **B. MARKET ANALYTICS**

**Table 10.** Italian Recent Past, Current & Future Analysis for Anti-Migraine Drugs –Annual Sales Figures in US\$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart)

**Table 11.** Italian Historic Analysis for Anti-Migraine Drugs – Annual Sales Figures in US\$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart)

## **2D.UNITED KINGDOM**

### **A. MARKET ANALYSIS**

Current & Future Analysis  
Historic Analysis

Migraine – Prevalence

Migraine Treatment

Abortive Drugs

List of Abortive Anti-Migraine Drugs Available in the UK

Prophylactic Drugs

List of Prophylactic Anti-Migraine Drugs Available in the UK

## **B. MARKET ANALYTICS**

**Table 12.** UK Recent Past, Current & Future Analysis for Anti-Migraine Drugs –Annual Sales Figures in US\$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart)

**Table 13.** UK Historic Analysis for Anti-Migraine Drugs – Annual Sales Figures in US\$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart)

## **2E.SPAIN**

### **A. MARKET ANALYSIS**

Current & Future Analysis

Historic Analysis

### **B. MARKET ANALYTICS**

**Table 14.** Spanish Recent Past, Current & Future Analysis for Anti-Migraine Drugs – Annual Sales Figures in US\$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart)

**Table 15.** Spanish Historic Analysis for Anti-Migraine Drugs – Annual Sales Figures in US\$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart)

## **2F.REST OF EUROPE**

### **A. MARKET ANALYSIS**

Current & Future Analysis



Historic Analysis  
Ireland

## **B. MARKET ANALYTICS**

**Table 16.** Rest of Europe Recent Past, Current & Future Analysis for Anti-Migraine Drugs – Annual Sales Figures in US\$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart)

**Table 17.** Rest of Europe Historic Analysis for Anti- Migraine Drugs – Annual Sales Figures in US\$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart)

## **III. COMPETITIVE LANDSCAPE**

Total Companies Profiled: 53 (including Divisions/Subsidiaries - 57)

Region/CountryPlayers

The United States

Canada

Japan

Europe

Germany

The United Kingdom

Italy

Spain

Rest of Europe

Asia-Pacific (Excluding Japan)

Middle-East

## I would like to order

Product name: Anti-Migraine Drugs: Market Research Report

Product link: <https://marketpublishers.com/r/A431247D60EEN.html>

Price: US\$ 3,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/A431247D60EEN.html>